Journal of Clinical Oncology MAY 28, 2021

Idecabtagene vicleucel (ide-cel) in relapsed and refractory multiple myeloma: The KarMMa study

Munshi NC, Anderson LD Jr, Shah N, et al.

Bottom Line

The phase 2 KarMMa trial demonstrated that the BCMA-directed CAR T-cell therapy idecabtagene vicleucel induces frequent, deep, and durable responses in patients with heavily pretreated, triple-class-exposed relapsed and refractory multiple myeloma.

Key Findings

1. The overall response rate (ORR) was 73% across all target dose levels (150–450 × 10^6 CAR-positive T cells).

2. A complete response (CR) rate of 33% was observed among the treated population.

3. The median overall survival (OS) for the total treated population was 24.8 months.

4. The safety profile included cytokine release syndrome (CRS) in 84% of patients (4% grade ≥3) and neurotoxicity in 18% of patients (3% grade ≥3).

5. Efficacy was dose-dependent, with the highest efficacy observed at the target dose of 450 × 10^6 CAR-positive T cells.

Study Design

Design

Phase 2 Trial

Open-Label

Sample

128

Patients

Duration

24.8 mo

Median

Setting

Multicenter, International

Population Adult patients with relapsed/refractory multiple myeloma who had received ≥ 3 prior regimens (including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody) and were refractory to their last treatment.

Intervention Single infusion of idecabtagene vicleucel (ide-cel) at target dose levels of 150, 300, or 450 × 10^6 CAR-positive T cells following lymphodepleting chemotherapy.

Comparator No concurrent control arm

Outcome Overall response rate (ORR)

Study Limitations

• Lack of a concurrent randomized control arm, complicating comparative assessments.

• Small sample size inherent to a phase 2 trial, limiting the ability to assess rare adverse events or generalize to all patient subsets.

• Heavily pretreated population at high risk of mortality, which may impact the assessment of long-term OS.

• The open-label study design may introduce bias in the reporting of subjective outcomes.

Clinical Significance

This study established idecabtagene vicleucel as the first FDA-approved CAR T-cell therapy for multiple myeloma, providing a critical therapeutic option for patients with limited remaining treatment choices who have exhausted standard-of-care therapies, including proteasome inhibitors, immunomodulatory agents, and anti-CD38 monoclonal antibodies.

Historical Context

The KarMMa trial represents a milestone in the treatment of multiple myeloma, marking the transition of chimeric antigen receptor (CAR) T-cell technology into the landscape of myeloma care, shifting the paradigm from purely pharmacological approaches to cell-based immunotherapy targeting the B-cell maturation antigen (BCMA).

Guided Discussion

High-yield insights from every perspective

Med Student

Medical Student

What is the mechanism of action of idecabtagene vicleucel (ide-cel), and why is the B-cell maturation antigen (BCMA) specifically targeted in the treatment of multiple myeloma?

Key Response

Ide-cel is a Chimeric Antigen Receptor (CAR) T-cell therapy that involves genetically modifying a patient's own T cells to express a receptor targeting BCMA. BCMA is an ideal target because it is highly and selectively expressed on the surface of malignant plasma cells and late-stage B cells, with virtually no expression on other essential tissues or hematopoietic stem cells, thereby minimizing off-target toxicity.

Resident

In the KarMMa study, what were the most common high-grade toxicities observed with ide-cel, and what clinical monitoring is essential during the first two weeks post-infusion?

Key Response

The study identified Cytokine Release Syndrome (CRS) and Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) as primary concerns. While CRS occurred in 84% of patients, only 5% were grade 3 or higher. Neutropenia (91%) and thrombocytopenia (63%) were also prevalent. Monitoring should focus on fever, hypotension, hypoxia (for CRS), and neurological changes using the ICE score (for ICANS), typically requiring inpatient observation or close daily follow-up.

Fellow

The KarMMa trial reported a median progression-free survival (PFS) of 8.8 months at the target dose of 450 x 10^6 CAR T cells. How does this compare to the 'real-world' outcomes of the MAMMOTH study for triple-class refractory patients, and what does this imply about the 'ceiling' of current CAR-T durability in myeloma?

Key Response

The MAMMOTH study showed a median PFS of only 3.4 months for triple-class refractory patients on conventional therapies. While ide-cel significantly more than doubles this, the sub-12-month PFS suggests that despite deep initial responses (CR/sCR), mechanisms of resistance such as BCMA antigen loss, CAR T-cell exhaustion, or an immunosuppressive bone marrow microenvironment remain significant hurdles for curative intent.

Attending

How should the requirement for 'bridging therapy' during the ide-cel manufacturing period—as utilized in the KarMMa trial—influence your selection of patients for this therapy in clinical practice?

Key Response

In KarMMa, 88% of patients received bridging therapy to maintain disease control while the CAR T cells were manufactured (approx. 4 weeks). This implies that patients with extremely aggressive, rapidly progressing disease who lack a viable bridging option may not survive to receive the infusion, making patient fitness and the presence of a 'holding' regimen critical factors in the referral decision.

Scholarly Review

Critical appraisal through the lens of expert reviewers and guideline development

PhD

The KarMMa trial demonstrated a clear dose-response relationship across the 150, 300, and 450 x 10^6 dose cohorts. From a translational perspective, what parameters of CAR T-cell expansion and persistence (Cmax and AUC) correlated most strongly with the depth of clinical response?

Key Response

Pharmacokinetic analysis in KarMMa showed that higher peak expansion (Cmax) and total exposure (AUC 0-28 days) were significantly associated with both higher doses and deeper clinical responses (CR or better). Understanding the factors that drive this expansion, such as the patient's endogenous T-cell fitness and the tumor burden (antigen load), is vital for optimizing future synthetic biology approaches to cell therapy.

Journal Editor

As a peer reviewer, how would you evaluate the impact of the single-arm, non-randomized design of the KarMMa study on its claim of clinical superiority over existing standards of care?

Key Response

While single-arm trials are common for breakthrough designations in refractory populations, they lack a direct comparator. A critical reviewer would flag that the 'intent-to-treat' population (all enrolled) vs. the 'treated' population (those who actually received the cells) can mask manufacturing failures or deaths during the wait time. The lack of a control arm makes it difficult to definitively account for the contribution of bridging therapies to the observed response rates.

Guideline Committee

Current NCCN and ASCO guidelines include ide-cel as a recommended therapy for relapsed/refractory multiple myeloma (RRMM). Based on the KarMMa data, what specific 'prior line' criteria must be met, and how do these findings influence the positioning of CAR-T versus bispecific T-cell engagers (BiTEs)?

Key Response

KarMMa focused on patients with at least three prior lines of therapy (triple-class exposed). Guidelines currently reflect this, placing ide-cel in the 4th line or later. While ide-cel offers a 'one-and-done' infusion benefit, the 20-30% rate of manufacturing failure or delay in real-world scenarios may lead guidelines to favor bispecifics (like teclistamab) for patients requiring immediate therapy, despite the need for continuous dosing.

Clinical Landscape

Noteworthy Related Trials

2015

ELOQUENT-2 Trial

n = 646 · NEJM

Tested

Elotuzumab plus lenalidomide and dexamethasone

Population

Relapsed or refractory multiple myeloma

Comparator

Lenalidomide and dexamethasone

Endpoint

Progression-free survival

Key result: The addition of elotuzumab to lenalidomide and dexamethasone significantly reduced the risk of disease progression or death compared to standard therapy alone.

2016

Pollux Trial

n = 569 · NEJM

Tested

Daratumumab plus lenalidomide and dexamethasone

Population

Relapsed or refractory multiple myeloma

Comparator

Lenalidomide and dexamethasone

Endpoint

Progression-free survival

Key result: Daratumumab combined with lenalidomide and dexamethasone significantly improved progression-free survival compared to lenalidomide and dexamethasone alone.

2021

CARTITUDE-1 Trial

n = 97 · NEJM

Tested

Ciltacabtagene autoleucel (cilta-cel)

Population

Relapsed and refractory multiple myeloma patients previously treated with three or more lines of therapy

Comparator

None (single-arm study)

Endpoint

Overall response rate

Key result: The study demonstrated a deep and durable response, with 97% of patients achieving a response and 67% achieving a stringent complete response.

Tailored to your role

Want this tailored to you?

Add your specialty or training stage to get role-specific takeaways and more questions.

Personalize this analysis